Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2023)
Inhibikase Therapeutics' (IKT) quarterly Non-Current Debt came in at $381784.0 in Q4 2023, up 53.38% on a QoQ basis from $248911.0 in Q3 2021.
Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 3 years of Non-Current Debt data on file, last reported at $381784.0 in Q4 2023.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $381784.0 in Q4 2023; TTM through Dec 2023 was $381784.0, a N/A change from a year earlier, with the FY2023 full-year figure at $381784.0, changed N/A from the prior year.
- Non-Current Debt for Q4 2023 stood at $381784.0, up from $248911.0 in the prior quarter.
- Over the last five years, Non-Current Debt for IKT reached as high as $1.2 million in Q1 2021 and fell as low as $248911.0 in Q2 2021.
- Historically, Non-Current Debt has averaged $479953.4 across 3 years, with a median of $276461.0 in 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 381,784.00 |
| Sep 30, 2021 | 248,911.00 |
| Jun 30, 2021 | 248,911.00 |
| Mar 31, 2021 | 1.24 Mn |
| Dec 31, 2020 | 276,461.00 |